Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077114 | 0.96 | CNR2 (0.84) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5214869 | 0.95 | CNR2 (0.82) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5213827 | 0.93 | CNR2 (1.00) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5251153 | 0.87 | CNR2 (0.79) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5212538 | 0.85 | CNR2 (0.93) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5215565 | 0.84 | CNR2 (0.70) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4648950 | 0.83 | CNR2 (0.72) | CNR2 | |
| SCHEMBL4649718 | 0.83 | CNR2 (0.96) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4648487 | 0.83 | CNR2 (1.00) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5079059 | 0.82 | CNR2 (0.98) | CNR2CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1718613-B1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1718613-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080342-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | CNR2, CNR1, TRPV1 | CNR2 1/4885CYP1A2 306/4885CYP3A4 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.